Catalysts for Boehringer Ingelheim Corp
113 tracked
Apr 2, 2026
approval
NINTEDANIB ESYLATE — FDA approval
Boehringer Ingelheim Corp
→
Feb 26, 2026
approval
HERNEXEOS (ZONGERTINIB) — FDA approval
zongertinib
→
Feb 26, 2026
approval
JASCAYD (NERANDOMILAST) — FDA approval
nerandomilast
→
Dec 19, 2025
approval
JASCAYD (NERANDOMILAST) — FDA approval
nerandomilast
→
Nov 3, 2025
approval
LINAGLIPTIN — FDA approval
Boehringer Ingelheim Corp
→
Oct 24, 2025
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Oct 24, 2025
approval
TRIJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin + metformin hydrochloride) ER
→
Oct 24, 2025
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Oct 24, 2025
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Oct 24, 2025
approval
SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + metformin hydrochloride ER)
→
Oct 21, 2025
approval
SPEVIGO (SPESOLIMAB-SBZO) — FDA approval
spesolimab
→
Oct 16, 2025
approval
CYLTEZO (ADALIMUMAB-ADBM) — FDA approval
CYLTEZO
→
Oct 7, 2025
approval
JASCAYD (NERANDOMILAST) — FDA approval
nerandomilast
→
Aug 8, 2025
approval
HERNEXEOS (ZONGERTINIB) — FDA approval
zongertinib
→
May 28, 2025
approval
SPEVIGO (SPESOLIMAB-SBZO) — FDA approval
spesolimab
→
May 28, 2025
approval
SPEVIGO (SPESOLIMAB-SBZO) — FDA approval
spesolimab
→
May 20, 2025
approval
CYLTEZO (ADALIMUMAB-ADBM) — FDA approval
CYLTEZO
→
Mar 7, 2025
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Mar 7, 2025
approval
SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + metformin hydrochloride ER)
→
Apr 30, 2024
approval
CYLTEZO (ADALIMUMAB-ADBM) — FDA approval
CYLTEZO
→
Mar 18, 2024
approval
SPEVIGO (SPESOLIMAB-SBZO) — FDA approval
spesolimab
→
Oct 30, 2023
approval
TRIJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin + metformin hydrochloride) ER
→
Oct 30, 2023
approval
SYNJARDY (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Oct 30, 2023
approval
GLYXAMBI (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + linagliptin)
→
Oct 30, 2023
approval
SYNJARDY XR (EMPAGLIFLOZIN) — FDA approval
(empagliflozin + metformin hydrochloride ER)
→
Sep 21, 2023
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Sep 12, 2023
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→
Jul 19, 2023
approval
CYLTEZO (ADALIMUMAB-ADBM) — FDA approval
CYLTEZO
→
Jun 30, 2023
approval
CYLTEZO (ADALIMUMAB-ADBM) — FDA approval
CYLTEZO
→
Jun 20, 2023
approval
JARDIANCE (EMPAGLIFLOZIN) — FDA approval
SYNJARDY
→